TGF-β insensitive dendritic cells: An efficient vaccine for murine prostate cancer

Cancer Immunology, Immunotherapy

Volumn 56, Issue 11, 2007, Pages 1785-1793

  Wang, Fu Li ^a   Qin, Wei Jun ^b   Wen, Wei Hong ^c   Tian, Feng ^a   Song, Bin ^a   Zhang, Qiang ^d   Lee, Chung ^d   Zhong, Wei De ^e   Guo, Ying Lu ^b   Wang, He ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY FIRST HOSPITAL   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^d NORTHWESTERN UNIVERSITY   (United States)

^e GUANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

Author keywords

Dendritic cell; Immuno gene therapy; Prostate cancer; Receptor; TGF ; Vaccination

Indexed keywords

DENDRITIC CELL VACCINE; GAMMA INTERFERON; INTERLEUKIN 12; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL ISOLATION; CELL LYSATE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; DRUG EFFICACY; FEMALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR REGRESSION; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CELL LINE, TUMOR; DENDRITIC CELLS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 34548173418     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0322-3     Document Type: Article

References (41)

1. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245-252
2. Banchereau J, Palucka AK (2005) Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5:296-306
3. Lee WC, Wang HC, Hung CF, Huang PF, Lia CR, Chen MF (2005) Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J Immunother 28:496-504
4. Chang GC, Lan HC, Juang SH, Wu YC, Lee HC, Hung YM, Yang HY, Whang-Peng J, Liu KJ (2005) A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma. Cancer 103:763-771
5. Kugler A, Stuhler G, Walden P, Zoller G, Zobywalski A, Brossart P, Trefzer U, Ullrich S, Muller CA, Becker V, Gross AJ, Hemmerlein B, Kanz L, Muller GA, Ringert RH (2006) Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 6:332-336
6. Sharma S, Stolina M, Yang SC, Baratelli F, Lin JF, Atianzar K, Luo J, Zhu L, Lin Y, Huang M, Dohadwala M, Batra RK, Dubinett SM (2003) Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res 9:961-968
7. Shurin GV, Shurin MR, Bykovskaia S, Shogan J, Lotze MT, Barksdale EM Jr (2001) Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res 61:363-369
8. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S (2000) Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74:181-273
9. Aalamian M, Pirtskhalaishvili G, Nunez A, Esche C, Shurin GV, Huland E, Huland H, Shurin MR (2001) Human prostate cancer regulates generation and maturation of monocyte-derived dendritic cells. Prostate 46:68-75
10. Ito M, Minamiya Y, Kawai H, Saito S, Saito H, Nakagawa T, Imai K, Hirokawa M, Ogawa J (2006) Tumor-derived TGFbeta-1 induces dendritic cell apoptosis in the sentinel lymph node. J Immunol 176:5637-5643
11. Gorelik L, Flavell RA (2001) Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 7:1118-1122
12. Kao JY, Gong Y, Chen CM, Zheng QD, Chen JJ (2003) Tumor-derived TGF-beta reduces the efficacy of dendritic cell/tumor fusion vaccine. J Immunol 170:3806-3811
13. Shah AH, Tabayoyong WB, Kimm SY, Kim SJ, Van Parijs L, Lee C (2002) Reconstitution of lethally irradiated adult mice with dominant negative TGF-beta type II receptor-transduced bone marrow leads to myeloid expansion and inflammatory disease. J Immunol 169:3485-3491
14. Shah AH, Tabayoyong WB, Kundu SD, Kim SJ, Van Parijs L, Liu VC, Kwon E, Greenberg NM, Lee C (2002) Suppression of tumor metastasis by blockade of transforming growth factor beta signaling in bone marrow cells through a retroviral-mediated gene therapy in mice. Cancer Res 62:7135-7138
15. Wikstrom P, Damber J, Bergh A (2001) Role of transforming growth factor-beta1 in prostate cancer. Microsc Res Tech 52:411-419
16. Yang EY, Moses HL (1990) Transforming growth factor beta 1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J Cell Biol 111:731-741
17. Enk AH, Jonuleit H, Saloga J, Knop J (1997) Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer 73:309-316
18. Wikstrom P, Stattin P, Franck-Lissbrant I, Damber JE, Bergh A (1998) Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 37:19-29
19. Shariat SF, Shalev M, Menesses-Diaz A, Kim IY, Kattan MW, Wheeler TM, Slawin KM (2001) Preoperative plasma levels of transforming growth factor beta (1) [TGF-beta (1)] strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol 19:2856-2864
20. Perry KT, Anthony CT, Case T, Steiner MS (1997) Transforming growth factor beta as a clinical biomarker for prostate cancer. Urology 49:151-155
21. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC (1999) Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol 161:182-187
22. Steiner MS, Zhou ZZ, Tonb DC, Barrack ER (1994) Expression of transforming growth factor-beta 1 in prostate cancer. Endocrinology 135:2240-2247
23. Kobie JJ, Wu RS, Kurt RA, Lou S, Adelman MK, Whitesell LJ, Ramanathapuram LV, Arteaga CL, Akporiaye ET (2003) Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res 63:1860-1864
24. Porgador A, Snyder D, Gilboa E (1996) Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 156:2918-2926
25. Liu F (2003) Receptor-regulated Smads in TGF-beta signaling. Front Biosci 8:s1280-s1303
26. Moustakas A, Pardali K, Gaal A, Heldin CH (2002) Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation. Immunol Lett 82:85-91
27. Chen RH, Ebner R, Derynck R (1993) Inactivation of the type II receptor reveals two receptor pathways for the diverse TGF-beta activities. Science 260:1335-1338
28. Zhang Q, Yang X, Pins M, Javonovic B, Kuzel T, Kim SJ, Parijs LV, Greenberg NM, Liu V, Guo Y, Lee C (2005) Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. Cancer Res 65:1761-1769
29. Zhang Q, Jang TL, Yang X, Park I, Meyer RE, Kundu S, Pins M, Javonovic B, Kuzel T, Kim SJ, Van Parijs L, Smith N, Wong L, Greenberg NM, Guo Y, Lee C (2006) Infiltration of tumor-reactive transforming growth factor-beta insensitive CD8+ T cells into the tumor parenchyma is associated with apoptosis and rejection of tumor cells. Prostate 66:235-247
30. Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM 1997 Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 57:3325-3330
31. Kao JY, Zhang M, Chen CM, Chen JJ (2005) Superior efficacy of dendritic cell-tumor fusion vaccine compared with tumor lysate-pulsed dendritic cell vaccine in colon cancer. Immunol Lett 101:154-159
32. Woo SC, Kim GY, Lee CM, Moon DO, Kim HK, Lee TH, Moon YS, Park NC, Yoon MS, Lee KS, Park YM (2005) The maturation of murine bone marrow-derived dendritic cells by tumor lysate uptake in vitro is not essential for cancer immunotherapy. Cancer Biol Ther 4:1331-1335
33. Chen Z, Moyana T, Saxena A, Warrington R, Jia Z, Xiang J (2001) Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. Int J Cancer 93:539-548
34. Rutella S, Lemoli RM (2004) Regulatory T cells and tolerogenic dendritic cells: from basic biology to clinical applications. Immunol Lett 94:11-26
35. Sato K, Kawasaki H, Nagayama H, Enomoto M, Morimoto C, Tadokoro K, Juji T, Takahashi TA (2000) TGF-beta 1 reciprocally controls chemotaxis of human peripheral blood monocyte-derived dendritic cells via chemokine receptors. J Immunol 164:2285-2295
36. Takayama T, Morelli AE, Onai N, Hirao M, Matsushima K, Tahara H, Thomson AW (2001) Mammalian and viral IL-10 enhance C-C chemokine receptor 5 but down-regulate C-C chemokine receptor 7 expression by myeloid dendritic cells: impact on chemotactic responses and in vivo homing ability. J Immunol 166:7136-7143
37. Hacker C, Kirsch RD, Ju XS, Hieronymus T, Gust TC, Kuhl C, Jorgas T, Kurz SM, Rose-John S, Yokota Y, Zenke M (2003) Transcriptional profiling identifies Id2 function in dendritic cell development. Nat Immunol 4:380-386
38. Strobl H, Knapp W (1999) TGF-beta1 regulation of dendritic cells. Microbes Infect 1:1283-1290
39. Wieser R, Attisano L, Wrana JL, Massague J (1993) Signaling activity of transforming growth factor beta type II receptors lacking specific domains in the cytoplasmic region. Mol Cell Biol 13:7239-7247
40. Slavin AJ, Tarner IH, Nakajima A, Urbanek-Ruiz I, McBride J, Contag CH, Fathman CG (2002) Adoptive cellular gene therapy of autoimmune disease. Autoimmun Rev 1:213-219
41. Mellman I, Steinman RM (2001) Dendritic cells: specialized and regulated antigen processing machines. Cell 106:255-258